Unknown

Dataset Information

0

Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.


ABSTRACT: MK-1775 is the first-in-class selective Wee1 inhibitor which has been demonstrated to synergize with CHK1 inhibitors in various malignancies. In this study, we report that the pan-histone deacetylase inhibitor (HDACI) panobinostat synergizes with MK-1775 in acute myeloid leukemia (AML), a malignancy which remains a clinical challenge and requires more effective therapies. Using both AML cell line models and primary patient samples, we demonstrated that panobinostat and MK-1775 synergistically induced proliferation arrest and cell death. We also demonstrated that panobinostat had equal anti-leukemic activities against primary AML blasts derived from patients either at initial diagnosis or at relapse. Interestingly, treatment with panobinostat alone or in combination with MK-1775 resulted in decreased Wee1 protein levels as well as downregulation of the CHK1 pathway. shRNA knockdown of CHK1 significantly sensitized AML cells to MK-1775 treatment, while knockdown of Wee1 significantly enhanced both MK-1775- and panobinostat-induced cell death. Our results demonstrate that panobinostat synergizes with MK-1775 in AML cells, at least in part through downregulation of CHK1 and/or Wee1, providing compelling evidence for the clinical development of the combination treatment in AML.

SUBMITTER: Qi W 

PROVIDER: S-EPMC4847803 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.

Qi Wenxiu W   Zhang Wenbo W   Edwards Holly H   Chu Roland R   Madlambayan Gerard J GJ   Taub Jeffrey W JW   Wang Zhihong Z   Wang Yue Y   Li Chunhuai C   Lin Hai H   Ge Yubin Y  

Cancer biology & therapy 20150101 12


MK-1775 is the first-in-class selective Wee1 inhibitor which has been demonstrated to synergize with CHK1 inhibitors in various malignancies. In this study, we report that the pan-histone deacetylase inhibitor (HDACI) panobinostat synergizes with MK-1775 in acute myeloid leukemia (AML), a malignancy which remains a clinical challenge and requires more effective therapies. Using both AML cell line models and primary patient samples, we demonstrated that panobinostat and MK-1775 synergistically in  ...[more]

Similar Datasets

| S-EPMC4282784 | biostudies-literature
| S-EPMC4237862 | biostudies-other
| S-EPMC5566030 | biostudies-literature
| S-EPMC3542630 | biostudies-literature
| S-EPMC3018695 | biostudies-literature
| S-EPMC5351636 | biostudies-literature
| S-EPMC3973087 | biostudies-other
| S-EPMC5341865 | biostudies-literature
| S-EPMC5756519 | biostudies-literature